Quoin Pharmaceuticals

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Quoin Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).

4 total trials 3 currently recruiting early-phase tilt upper quartile by trial count

Quoin Pharmaceuticals: 4 sponsored US clinical trials, 3 recruiting.

Quoin Pharmaceuticals sponsors 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Netherton Syndrome, with 3 trials.

Upper-quartile sponsor footprint

Quoin Pharmaceuticals sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

What is open in the Quoin Pharmaceuticals pipeline

3 recruiting of 4 indexed (75% open).

Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).

Top condition: Netherton Syndrome (3 trials), 0 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Quoin Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 4 registered trials and 75% open enrollment, not the therapeutic-area sidebar.

Quoin Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 3.94.04.044.04.04.1 0%20%40%60%80% Total trials Recruiting share Quoin Pharmaceuticals4D pharma60 Degrees PharmaceuticalsA2 BiotherapeuticsAbdul Latif Jameel Poverty Action LabAcepodia BiotechAmerican Laboratory Products CompanyAmryt PharmaAmydis
Quoin Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Quoin Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 4 trials (± recruiting share)

Sponsors near 75% open enrollment (± trial volume)

What to do with this Quoin Pharmaceuticals page

4 registered trials is a research-attention snapshot, not an endorsement of Quoin Pharmaceuticals or any single study.

  • 3 of Quoin Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Netherton Syndrome is the condition Quoin Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Netherton Syndrome trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Quoin Pharmaceuticals pipeline card: 4 registered trials from official public datasets.Report a data error.